Real-world experience of second-line axitinib in metastatic renal cell carcinoma: analysis of the Swedish population.

导出 OA

翻译打印收藏纠错

作者： Maria,Jakobsson ^[1] ; Angela,Strambi ^[2] ; Fredrik,Nilsson ^[1] ; Johannes,Arpegård ^[1] ; Johan,Dalén ^[3]

作者单位： Pfizer AB, 113 63 Stockholm, Sweden. ^[1] Fondazione Toscana Life Sciences, 53100 Siena, Italy. ^[2] ICON plc, 111 22 Stockholm, Sweden. ^[3]

关键词 axitinib metastatic renal cell carcinoma real-world second-line axitinib

主题词成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);女(雌)性(Female);人类(Humans);男(雄)性(Male);中年人(Middle Aged);癌, 肾细胞(Carcinoma, Renal Cell);吲唑类(Indazoles);肾肿瘤(Kidney Neoplasms);蛋白激酶抑制剂(Protein Kinase Inhibitors);嘧啶类(Pyrimidines);回顾性研究(Retrospective Studies);磺胺类(Sulfonamides);瑞典(Sweden);治疗结果(Treatment Outcome)

DOI 10.1080/14796694.2024.2351352

PMID 39057291

发布时间 2024-09-07

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Future oncology (London, England)

2024年20卷20期

1385-1392页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Real-world experience of second-line axitinib in metastatic renal cell carcinoma: analysis of the Swedish population.

Future oncology (London, England)

相似文献

Future oncology (London, England)

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Real-world experience of second-line axitinib in metastatic renal cell carcinoma: analysis of the Swedish population.

Future oncology (London, England)

相似文献

Future oncology (London, England)

相关期刊

检索历史清除